For women with pathogenic/likely pathogenic variants in BRCA1/2, some risk-reducing strategies, such as prophylactic surgeries, have demonstrated reduced cancer risk and mortality in some studies [42–44], but not others [45]. The gene discussed is BRCA1; the disease is cancer.